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Substance abuse and/or dependence are common problems 
among the general population, and evidence indicates that 
the incidence is even higher in individuals with mental health 
problems. In 2007, the US Substance Abuse and Mental Health 
Services Administration reported that, of the 24.9 million adults 
found to have a severe mental illness, 27.2% had used an 
illicit substance within the past year, and 22.3% met abuse or 
dependence criteria. Comparative figures for individuals without 
a severe mental illness were much lower, at 12.3% and 7.7% 
respectively.1 Cannabis is currently the world’s foremost illicit 
substance consumed – the United Nations estimates that it is used 
by 3.9% of the world’s adult population.2
Co-morbid substance abuse is a confirmed risk factor for poorer 
symptomatic and functional outcomes in individuals with mental 
illness.3,4 Furthermore, service costs for individuals with, for 
example, a dual diagnosis of schizophrenia and substance 
abuse, can be twice that for patients without such diagnoses.5
The rate of co-morbid cannabis consumption in individuals with 
schizophrenia is reportedly high. In their review of 53 clinical 
studies, Green et al. found that the lifetime prevalence of 
cannabis use was 42.2%, and of cannabis misuse, 22.5%.6 A 
number of correlates and risk factors predicting substance use in 
schizophrenia populations have emerged with some consistency. 
These include being unmarried, being male, and having lower 
educational levels, a childhood conduct disorder or a co-morbid 
antisocial personality disorder.3,7-9
Although research on the effects of cannabis abuse on clinical 
parameters in individuals with schizophrenia has produced 
conflicting results, two prospective studies attempting to examine 
the longer-term outcome of cannabis use in this illness have both 
demonstrated poorer outcome and increased intensity of positive 
symptoms.10,11 A number of prospective epidemiological studies 
also now provide support for the hypothesis that cannabis abuse 
increases the subsequent risk for developing schizophrenia.12-14
In South Africa, the exact prevalence of cannabis use/abuse 
among the general population, as well as among individuals 
with mental disorders, has not been formally studied, but it is 
generally believed to be high. Peltzer and Ramlagan recently 
reviewed cannabis use trends (over a period of 12 years) in 
the South African population, by sourcing data from surveys, 
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Objective. Worldwide, cannabis is the most widely used 
illicit substance, and it has been identified as a correlate in 
schizophrenia samples for poorer symptomatic and functional 
outcomes in many international studies. The object of this 
retrospective study was to identify the prevalence of cannabis 
use/abuse and the demographic and clinical correlates 
therefor in a large homogeneous South African schizophrenia 
population.
Methods. As part of a large genetic study, 547 subjects with a 
diagnosis of schizophrenia were recruited. Demographic and 
clinical data were collected and each participant underwent a 
urinary drug screen. Use/abuse of cannabis was defined as 
using cannabis more than 21 times in a single year. Subjects 
with and without cannabis use/abuse were statistically 
compared.
Results. Significant differences between the two groups 
were found in terms of gender, marital status, age of onset 
of schizophrenia, number of hospitalisations and relapses, 
alcohol abuse, smoking, the Scale for the Assessment of 
Positive Symptoms (SAPS) scores for hallucinations, delusions, 
bizarre behaviour and formal thought disorder, and the Scale 
for the Assessment of Negative Symptoms (SANS) score for 
avolition/apathy. 
Conclusion. The prevalence of cannabis use/abuse in this 
study was high, and our findings were comparable with those 
of previous international studies. Abuse/use started mainly in 
the teenage years, was more prevalent among males than 
females, and was associated with negative overall outcomes. 
There was also a positive correlation between cannabis and 
nicotine and alcohol use/abuse. Determination of cannabis 
abuse based solely on history was found to be reliable, and 
urine cannabis testing appeared to be of limited value in 
routine management of this group of schizophrenic patients.
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specialised alcohol and drug treatment centres, cannabis-related 
trauma unit admissions, and arrestee studies.15 They concluded 
that cannabis was the most common illicit substance used, with 
current self-reported cannabis use of 5 - 10% among adolescents 
and 2% among adults. Furthermore, it was higher among men 
than women, higher in urban than rural areas, higher in the 
urban provinces of Western Cape and Gauteng than the other 
provinces, and higher among coloureds and whites than other 
racial groups.
Currently, no structured data exist for co-morbid cannabis use/
abuse in a South African schizophrenia population. However, 
some data have been reported, including a 46% lifetime 
prevalence of cannabis abuse in a study of HIV/AIDS risk-
behaviour in a sample of 102 outpatients.16 Another study looking 
at risk factors for violence in a schizophrenic inpatient population, 
showed lifetime cannabis abuse to be 33% in the violent sample, 
and 27% in the non-violent sample.17
In view of the paucity of existing data, the purpose of this 
study was therefore to try to identify the demographic and 
clinical correlates of cannabis abuse in a large South African 
schizophrenia group. To limit confounding factors, a decision was 
made to use an ethnically homogeneous population.
Methods
From 2002 to 2005, participants were recruited from inpatient 
units and outpatient community clinics in the larger Cape Town 
metropole as part of an ongoing genetic study. Inclusion criteria 
were: (i) a diagnosis of schizophrenia according to DSM-IV-TR 
criteria: and (ii) Xhosa ethnicity (with 4/4 grandparents reported 
to be Xhosa). Men and women aged 18 - 65 years at all stages 
of illness were included.
All participants were interviewed by a trained psychiatrist and/or 
a Xhosa psychiatric nurse with extensive clinical experience, 
using a standardised interview – the Diagnostic Interview for 
Genetic Studies (DIGS) Version 2.0, which includes the Scales 
for the Assessment of Positive (SAPS) and Negative Symptoms 
(SANS).18 Both the SANS and the SAPS have subscales, with 
scores from 0 to 5 possible for each subscale. The Abnormal 
Involuntary Movement Scale (AIMS) was also completed for each 
participant.19
Interviews were supplemented by hospital/clinic chart records 
and collateral information from family members, where available. 
Patients were also questioned on their use of substances of abuse, 
and a urinary drug screen was performed on all participants. 
Use/abuse of cannabis was defined as using cannabis more 
than 21 times in a single year, based on the DIGS criteria. The 
urinary drug screen was specific for detecting cannabis use in the 
last 30 days. The test strip used was the One Step Marijuana Test 
Strip produced by Acon Laboratories, which has high sensitivity 
and specificity.
For the purposes of this study, the following demographic and 
clinical correlates were retrospectively investigated: cannabis 
use/abuse, age at start of cannabis use/abuse, duration of 
cannabis use/abuse, age, gender, marital status, level of 
education, employment status, smoking status, and alcohol abuse 
and dependence.
For the purposes of statistical analysis, patients were divided into 
two groups: (i) cannabis users/abusers; and (ii) non-cannabis 
users/abusers. Descriptive and comparative study analyses 
between the two groups were performed using independent 
Student’s t-tests and chi-squared tests. The statistical package used 
was Microsoft Excel with WinStat.
All patients provided written informed consent, and the ethical 
guidelines as stipulated by the Committee for Human Research of 
Stellenbosch University were strictly adhered to.
Results
Demographic variables
The original study recruited 547 participants, of whom 52 were 
excluded owing to insufficient data regarding their history of 
cannabis use/abuse. Based on a history of use/abuse and/or 
positive urine test, 245 participants were grouped as cannabis 
users/abusers (CUA); this group included one participant who 
denied cannabis use/abuse but who tested positive on urine 
cannabis testing. Two hundred and fifty participants were 
grouped as non-cannabis users/abusers (NCUA).
The study group consisted of 410 male and 85 female 
participants, with an overwhelming majority of males (98.8%; 
N=242) among the CUAs. Among the NCUAs, 67.2% (N=168) 
were male and 32.8% (N=82) were female. The gender 
distribution difference between the two groups was statistically 
significant (p<0.0001). Table I shows additional demographic 
variables.
Illness variables
Table II summarises the illness variables.
Substance variables
The current prevalence rate of cannabis use/abuse for the 
whole sample was 49.5%. Ninety-five participants (CUA=94, 
NCUA=1) had a positive cannabis urinary drug screen on 
interview. The screen revealed no positive tests for any of the 
other drugs of abuse (methamphetamine, opiates, cocaine, 
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methaqualone). On interview, 17 participants admitted to lifetime 
methaqualone use, and one each to cocaine and opiates.
The mean age at start of cannabis use/abuse was 20.2 years (SD 
7.36, range 9 - 52). Data on the length of time that participants 
used/abused cannabis were available for only 41.2% (N=103) 
participants. Of these, 40.2% (N=39) had used/abused 
cannabis for ≤1 year , 6.2% (N=6) for between 1 and 2 years, 
7.2% (N=7) for between 2 and 3 years, and 52.5% (N=51) for 
≥4 years. Table III presents additional substance variables.
Clinical variables
Statistically significant differences between the two groups 
could be documented for all of the positive symptom subscores 
as recorded on the SAPS. With reference to negative symptom 
subscores as recorded on the SANS, the only difference reported 
was that for the avolition/apathy subscale, with significantly 
higher scores for the CUA group (p<0.0001). Table IV presents 
full clinical variables.
Discussion
The overall lifetime prevalence of cannabis use/abuse in our 
study was 49.49%, which was comparable to the mean 42.2% 
lifetime prevalence of cannabis use (range 19 - 89%) reported by 
Green et al. in their review of 53 treatment samples.6
Of particular note was the apparent reliability of participants’ 
responses with reference to their use/abuse status. Only 
one participant denied any use/abuse on history and was 
subsequently found to test positive on urine screen. A ‘no’ therefore 
represented a strong negative predictor of cannabis use/abuse. 
Of the group who admitted to be positive for cannabis use/abuse, 
only 94 (38.3%) were confirmed positive on urine testing. Taking 
into account that (i) having a history of cannabis use/abuse does 
not mean that one is currently using/abusing cannabis; and (ii) 
our group was heterogeneous in terms of hospitalisation status, 
this was not an unexpected finding. Therefore, our findings raise 
the question of the value of actual testing (v. only taking a history) 
for cannabis use/abuse in our setting, taking into account our 
severely financially constrained health system.
Our dataset replicated previous findings about associations 
between cannabis use/abuse and male gender, single status and 
increased rates of relapses and hospitalisations.3,7-9 In contrast, 
employment status and educational levels were not found to be 
correlates for cannabis use/abuse;7,20 however, this could have 
been influenced by the overall low level of formal employment for 
our total sample which, unfortunately, was in keeping with a high 
Table I. Comparison of demographic variables between can-
nabis users/abusers (CUA) and non-cannabis users/abusers 
(NCUA)
  
CUA NCUA p-value
Age at interview (yrs) 37 (SD 
9.63, 
range  
15 - 70)
33 (SD 
11.88, 
range    
17 - 64)
NS 
Marital status (N)
Divorced 6
8
43
13
174
9
3
169
8
70
3
18
60
70
53
39
4
2
4
NS
Married 11 *<0.001
Separated 7 NS
Single 218 *<0.001
Widowed 2 NS
Missing data 1 NS
Employment status (N)
Disability 150 NS
Employed 8 NS
Unemployed 85 NS
Missing data 2 NS
Education (N)
No schooling 4 NS
<Grade 7 58 NS
Grade 7 91 NS
Grade 10 52 NS
Grade 12 36 NS
 Trade/apprentice-
ship
1 NS
Diploma 1 NS
Missing data 2 NS
*Significance at p<0.05 level.
Table II. Comparison of illness variables between CUA and NCUA groups
CUA                   NCUA  p-value
Age at onset of symptoms 21.2 (SD 4.51, range 11 - 38) 25.3 (SD 8.16, range 10 - 55) *<0.0001
Mean number of hospitalisations 3.8 (SD 4.49, range 0 - 21) 2.9 (SD 3.23, range 0 - 16) *<0.001
Mean number of relapses 4 (SD 4.80, range 1 - 21) 3.1 (SD 2.97, range 0 - 11) *<0.001
*Significance at p<0.05 level.
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national unemployment rate. Also deeply worrying was that a 
third of the participants who were unemployed were not receiving 
a social grant.
As demonstrated previously in the literature, our study group also 
showed a lower mean age of onset of illness in the cannabis use/
abuse group.7 Three possible mechanisms have been suggested 
in the literature to explain this finding: Firstly, it is possible that 
cannabis has no influence on risk or age at onset, and that 
younger patients, compared with older patients, are more likely 
to use this substance before the first psychotic episode because 
its use is also age-related.21 Secondly, cannabis use could hasten 
the onset of psychosis in individuals who would have developed 
this disorder even if they had never used the substance; this 
notion is supported by evidence suggesting that cannabis may 
trigger or exacerbate psychotic symptoms in healthy individuals 
and schizophrenic patients.22 A third suggested mechanism is 
that cannabis lowers the threshold for developing schizophrenia 
in those genetically at risk for developing it. It is known that the 
enzyme catechol-O-methyltransferase (COMT) plays an essential 
role in the breakdown of dopamine in the prefrontal cortex. Caspi 
et al. has shown that COMT moderates the influence of adolescent 
cannabis use, with at least a fivefold increased risk of developing 
schizophreniform disorder in cannabis users homozygous for the 
high activity Val allele. In contrast, homozygosity for the Met allele 
offered relative protection (odds ratio 1.1), whereas the risk for 
heterozygotes was intermediate (odds ratio 2.5).23
Both nicotine and alcohol use/abuse were common in our entire 
sample, but there were almost twice the number of nicotine 
users, and three times the number of alcohol abusers, in the 
cannabis use/abuse group. Overall, there was a 22.4% lifetime 
prevalence of alcohol abuse in the total sample of 547, which is 
almost twice the 11.4% lifetime prevalence rate of alcohol abuse 
recently reported for the general South African population.24 Very 
few other substances of abuse were reported in our sample, 
which is similar to findings of other previously reported South 
African schizophrenia samples.17,25
The absence of methamphetamine use/abuse in our sample, in 
view of the current high prevalence rates of methamphetamine 
use/abuse in the Western Cape, is notable.26 Possible 
explanations for this could be that it only appeared to become 
a popular drug of abuse towards the end of 2004, and our 
sample of patients was assessed between 2002 and 2005. 
Secondly, cannabis has for generations been regarded as 
a traditional drug among the indigenous southern African 
populations, and its use has therefore possibly been associated 
with low moral blameworthiness.27 Thirdly, the relatively higher 
Table III. Comparison of substance variables between CUA and 
NCUA groups
CUA 
(N)
NCUA 
(N) p-value
Alcohol abuse 81 29 *<0.001
Alcohol dependence 4 3 NS
Nicotine use 232 136 *<0.0001
*Significance at p<0.05 level.
Table IV. Comparison between CUA and NCAU groups with 
reference to SAPS and SANS subscores and AIMS total score
Mean SD p-value
Affective flattening/blunting
NCUA
CUA
Total
2.21 1.2
0.0785
2.40 1.2
2.31 1.2
Alogia
NCUA
CUA
Total
1.57 1.50
0.1264
1.78 1.47
1.67 1.5
Avolition/apathy
NCUA
CUA
Total
2.25 1.13
*0.0038
2.54 1.08
2.39 1.1
Anhedonia/asociality
NCUA
CUA
Total
2.60 0.99
0.1892
2.72 1.05
2.66 1.0
Attention
NCUA
CUA
Total
0.56 1.10
0.0842
0.74 1.22
0.65 1.2
Hallucinations
NCUA
CUA
Total
1.68 1.68
*0.0199
2.03 1.62
1.86 1.7
Delusions
NCUA
CUA
Total
1.66 1.58
*0.0053
2.07 1.63
1.87 1.6
Bizarre behaviour
NCUA
CUA
Total
1.08 1.46
*0.0001
1.71 1.59
1.39 1.6
Formal thought disorder
NCUA
CUA
Total
1.02 1.38
*0.0014
1.46 1.58
1.24 1.5
AIMS
NCUA
CUA
Total
1.34 3.61
0.8604
1.28 3.41
1.31 3.5
*Significance at p<0.05 level.
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costs of methamphetamines might have made cannabis a more 
favourable option.
In keeping with previous data, cannabis use/abuse was shown 
to be associated with a significantly increased prevalence of 
positive symptoms that included hallucinations, delusions, formal 
thought disorder and bizarre behaviour.3,10,11 However, it should 
be noted that more of the cannabis use/abuse group were 
inpatients at the time of the assessment, although the difference 
between the two groups was not statistically significant.
In our study, the mean AIMS score was lower (but not statistically 
significant) for the cannabis use/abuse group. These findings 
were expected as this sample overlapped with that reported on 
by Niehaus et al. whose results suggest that cannabis abuse 
might be protective against involuntary movements.28 Muller-
Vahl proposed that tetrahydrocannabinol (THC) protects against 
movement disorders by stimulating release of dopamine from 
dopaminergic projections from the substantia nigra ending in the 
striatum.29 It is known that deficiencies of this pathway may cause 
movement disorders.
Possible limitations of this study included the following: (i) 
assessment instruments were not translated into Xhosa; (ii) the 
assessment relied on historical information with possible recall 
bias; and (iii) the group sample was mixed with regard to 
hospitalisation status and, therefore, stage of illness.
Strengths of this study included the use of (i) a large, ethnically 
homogeneous population; (ii) validated structured clinical 
interviews; and (iii) multiple sources of information.
Conclusion   
The prevalence of cannabis use/abuse in our study population 
was found to be significant and comparable with previous 
international studies. Cannabis use/abuse started mainly in 
the teenage years, was more prevalent among males and was 
found to have a negative association with outcome, in terms of 
the degree of symptomatology as well as rates of hospitalisations 
and relapses. The prevalence of co-morbid alcohol and nicotine 
abuse was also found to have a positive correlation with 
cannabis use/abuse. Taken together, our findings underscore 
the clear need for a targeted dual diagnosis service to improve 
outcomes for our clients. Finally, our study results also seem to 
suggest that the practice of urine cannabis testing appears to 
add little value in routine management of known schizophrenic 
patients. A thorough interview with reliable collateral information 
would seem to be sufficient to exclude substance abuse in the 
majority of such cases.
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